Allergan, Inc. v. Sandoz Inc, No. 6:11-cv-00441 (E.D. Tex. Mar. 27, 2013)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

On September 27, 2012, the Court held a claim construction hearing to construe disputed terms. Since then, additional patents have issued which the parties agreed to consolidate into this litigation. The Court granted the parties’ request to construe additional terms. Accordingly, this order addresses the disputed claim terms of U.S. Patent Nos. 8,278,353 (‘353 patent) and 8,299,118 (‘118 patent). 1 Defendants primarily argue that the asserted claims of the ‘353 and ‘118 patents are invalid for indefiniteness.